A smorgasbord of new agents
Biotech Strategy Blog
by MaverickNY
14h ago
Every now and then what seems like one player out in left field for the longest time suddenly balloons into ..read more
Visit website
All is not what it seems
Biotech Strategy Blog
by MaverickNY
5d ago
Lately the cancer research space is abuzz with the promise of several novel therapeutic approaches, each touted as the next ..read more
Visit website
The Eye of the Tiger
Biotech Strategy Blog
by MaverickNY
1w ago
Inspired by some local San Diego street art during the AACR meeting last week, my thoughts were immediately drawn to ..read more
Visit website
Kicking KRAS to the kerb
Biotech Strategy Blog
by MaverickNY
1w ago
It’s very rare for any oncology category to see lasting success with the first couple of attempts to drug a ..read more
Visit website
Lessons learned from AACR24 – Part 1
Biotech Strategy Blog
by MaverickNY
2w ago
The AACR annual meeting is an opportunity to challenge established paradigms and scientific dogma. In this post, we’re highlighting some ..read more
Visit website
How creative thinking can turn our heads
Biotech Strategy Blog
by MaverickNY
2w ago
For the longest time many folks have been rather bearish when it comes to drugging seemingly intractable targets in oncology ..read more
Visit website
On biomarkers and bispecifics
Biotech Strategy Blog
by MaverickNY
3w ago
Have you often wondered about the challenges of going into the unknown with phase 1 or even phase 3 trials ..read more
Visit website
Cancer’s Tiny Doppelgangers
Biotech Strategy Blog
by MaverickNY
1M ago
In our penultimate preview of the AACR24 meeting in San Diego – there’s one more to come folks – we ..read more
Visit website
Just can’t get enough
Biotech Strategy Blog
by MaverickNY
1M ago
The dawn of the 1980s represented a much more optimistic future than what it eventually turned out to be ..read more
Visit website
Molecular Jiu-Jitsu – Turning Cancer’s Mistakes Against Itself
Biotech Strategy Blog
by MaverickNY
1M ago
Synthetic lethality has always seemed a great idea on paper, yet the very nature of tumour complexity has frequently hampered ..read more
Visit website

Follow Biotech Strategy Blog on FeedSpot

Continue with Google
Continue with Apple
OR